R&D Proving ROI for digital endpoints The costs associated with clinical trials are a major bottleneck to drug development and affordability.
Digital Fuelling the efficiency of drug development through sensor d... Who remembers that line from the movie Zoolander, “the files are IN the computer?!” Twenty years later and we’re now all painfully
Digital The year ahead in digital health and life sciences: the phar... In the latest episode of the pharmaphorum podcast, editor in chief Jonah Comstock speaks with Jennifer Goldsack, CEO of the Digital Medicine Society (DiMe).
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
